Self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-sc) is feasible, acceptable, and effective. Our objective was to compare one-year continuation of DMPA-sc between women randomized to self-administration versus clinic administration. We randomized 401 females ages 15–44 requesting DMPA at clinics in Texas and New Jersey to self-administration or clinic administration in a 1:1 allocation. Clinic staff taught participants randomized to self-administration to self-inject and observed the first injection; participants received instructions, a sharps container, and three doses for home use. Participants randomized to clinic administration received usual care. All participants received DMPA-sc at no cost and injection reminders via text message or email. We conducted follow-up surveys at six and 12 months.
Institutional author(s): Planned Parenthood
Individual author(s): Julia E. Kohn, Hannah R. Simons, Lisa Della Badia, Elissa Draper, Johanna Morfesis, Elizabeth Talmont, Anitra Beasley, Melanie McDonald, Carolyn L Westhoff
Publication date: December, 2017